Table 4 |
|||||
|
Results of fluorescence in situ hybridisation (HER2) and immunohistochemical staining (HER1–HER4) |
|||||
| FISH |
Immunohistochemistry |
||||
|
|
|||||
| HER2 |
HER1 |
HER2 |
HER3 |
HER4 |
|
| Evaluation characteristics |
n = 231 |
n = 178 |
n = 214 |
n = 173 |
n = 191 |
|
|
|||||
| 0 |
n.r. |
152 (85.4) |
112 (52.4) |
43 (24.9) |
120 (62.8) |
| 1+ |
n.r. |
7 (3.9) |
54 (25.2) |
115 (66.5) |
49 (25.7) |
| 2+ |
n.r. |
11 (6.2) |
26 (12.1) |
14 (8.1) |
17 (8.9) |
| 3+ |
n.r. |
8 (4.5) |
22 (10.3) |
1 0.5) |
5 (2.6) |
| Positive |
46 (19.9) |
26 (14.5) |
48 (22.4) |
130 (75.1) |
71 (37.2) |
| Negative |
185 (80.1) |
152 (85.5) |
166 (77.6) |
43 (24.9) |
120 (62.8) |
|
|
|||||
|
Numbers in parentheses are percentages. The total sample size was n = 278. Results in bold define data considered positive for immunohistochemistry. FISH, fluorescence in situ hybridisation; n.r. = non-relevant for FISH; cut-off point for HER2 FISH analysis (≤1.5 vs. ≥1.6) distinguishes amplified (positive) or normal (negative) gene status. |
|||||
|
Sassen et al. Breast Cancer Research 2008 10:R2 doi:10.1186/bcr1843 |
|||||
